Pharmacokinetic Clinical Trial
Official title:
Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults
Verified date | December 2021 |
Source | Zhongnan Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
1. To explore the relationship between the changes of plasma concentration of abiraterone acetate after taken orally on fasting or postprandial and gene polymorphism. 2. Study of drug Metabolite profiling after oral administration of abiraterone acetate on fasting and postprandial in Chinese adults.
Status | Active, not recruiting |
Enrollment | 81 |
Est. completion date | July 1, 2022 |
Est. primary completion date | August 20, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Age: Healthy male subjects aged 18 to 65 years - Weight: weight =50.0kg, 19 = BMI = 26 kg/m2, BMI=weight (kg) / height2(m2) - Fully aware of the purpose, nature, method and possible adverse reactions of the study, and sign informed consent prior to the commencement of any study procedure on a voluntarily base. - Be able to communicate well with the investigator and understand and abide by the terms of the study requirements. Exclusion Criteria: - Clinical laboratory examination is abnormal and clinically significant. - Vital signs examination is abnormal and clinically significant, or there are other diseases of clinical significance(Including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardio-cerebrovascular disease)or other specific systemic disease. - Electrocardiogram is abnormal and clinically significant. - HbsAg, Anti - HCV, TPPA, or HIV antibody positive. - History of allergy to abiraterone acetate tablets or its ingredients and analogs - The number of daily smoking >5 during 3 months before the trial. - Alcoholics or regular drinkers in the 6 months prior to the trial, that is drinking more than 14 units per week (1 Unit =360mL beer or 45mL 40% liquor or 150mL wine) - Positive for drug, has a history of drug abuse in the past five years or has used drugs in the 3 months prior to the trial. - Positive for alcohol screening or use of any alcoholic product within 24 hours prior to taking the study drug. - Blood donation or massive blood loss within 3 months prior to taking the study drug (>450mL). - Take any xanthine rich beverage, food, grapefruit fruit or products that contain grapefruit in 48 hours before the trial. - Take in chocolate or any food or drink containing caffeine in 48 hours before the trial. - A history of dysphagia or any gastrointestinal disease that affect drug absorption. - Have taken the study drug or participated in the drug or medical device within three months before this trial. - There are major changes in diet or exercise habits recently. - Acute disease occurs during the study screening phase or prior to taking study drugs. - There are drug combination of CYP3A4, P-GP, or Bcrp inhibitors or inducers (such as itraconazole, ketoconazole, dronedarone et al.), or any drugs that affect hepatic microsomal enzyme activity during the 28 days before taking the study drug. - Accompanied by any coagulation disorders (such as Willebrand's disease or hemophilia) or history of hemorrhagic disease. - Accompanied by any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis, stomach or duodenal ulcers, etc. - Special requirements on diet and fails to comply with the diet provided and the corresponding regulations, especially for the lactose intolerant. - History of asthma or seizures. - Have a pregnancy plan in 6 months, sperm or egg donation, or reluctance to use one or more non-drug contraceptives during the trial. - Taking any prescription drugs, nonprescription drug, over-the-counter, vitamin products, or herbal medicines in 14 days before taking the study drug. - Patients with abnormal nucleic acid or antibody detection of COVID-19 and considered ineligible by the investigator. - Pulmonary CT were abnormal and considered inappropriate to participate in the study by the investigator. - Subjects considered to have poor compliance or have any factors that would make them inappropriate to participate in the study. |
Country | Name | City | State |
---|---|---|---|
China | Zhongnan Hospital of Wuhan University | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Zhongnan Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Concentrations of abiraterone in plasma | -1h, 30min, 1h , 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h after administration for blood sampling | 2 months | |
Primary | Cmax | peak concentration | 2 months | |
Primary | AUC0-t | Area under curve. The linear trapezoid method is used to calculate the blood drug concentration from zero to the last measurable concentration area under the curve | 2 months | |
Primary | AUC0-8 | The area under the blood concentration-time curve from zero to infinite blood concentration | 2 months | |
Primary | ?z | End phase elimination rate constant, the least square method is used to find the slope of the optimal curve for phase elimination And multiplied by 2.303 | 2 months | |
Primary | T1/2z | Elimination or final half-life, 0.693/?z | 2 months | |
Primary | AUC_%Extra | [(AUC0-8- AUC0-t)/ AUC0-8]×100%, Percentage of residual area | 2 months | |
Primary | Vz/F | apparent volume of distribution, Vz/F = CLz/F /?z | 2 months | |
Primary | CLz/F | apparent clearance, CLZ /F= administration dose /AUC0-8 | 2 months | |
Primary | the main metabolite of abiraterone | The plasma, urine and feces samples were collected to assay the metabolic profile of abiraterone in vivo by UFLC-Q-Exactive Orbitrap HRMS system | 2 months | |
Primary | genotyping related to abiraterone metabolism | Mutation sites of transporter and metabolic enzyme related to abiraterone metabolism were detected through the gene detection technology service platform | 10 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04531150 -
Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects
|
Phase 1 | |
Completed |
NCT03437265 -
A Pharmacokinetic Study of PLENVU® in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03979989 -
Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)
|
Phase 1 | |
Completed |
NCT00743912 -
Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05367011 -
Therapeutic Monitoring of Antibiotics in Intensive Care Patients: a Cohort Study PopTDM-ICU
|
||
Completed |
NCT06126562 -
A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects
|
Phase 1 | |
Completed |
NCT00745264 -
Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise
|
Phase 1 | |
Completed |
NCT03344627 -
Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients
|
N/A | |
Completed |
NCT01082796 -
Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects
|
N/A | |
Terminated |
NCT02696954 -
Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects
|
Phase 1/Phase 2 | |
Recruiting |
NCT03714568 -
Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.
|
Phase 1 | |
Recruiting |
NCT04080895 -
Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03011996 -
To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration
|
Phase 1 | |
Completed |
NCT00681395 -
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
|
Phase 1 | |
Completed |
NCT04617509 -
A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248
|
Phase 1 | |
Terminated |
NCT03059511 -
Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants
|
Phase 1 | |
Withdrawn |
NCT05938608 -
A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body
|
Phase 1 | |
Completed |
NCT01091532 -
A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.
|
Phase 1 | |
Completed |
NCT03951402 -
Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women
|
Phase 1 | |
Completed |
NCT03882762 -
A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol
|
Phase 1 |